US HB2889 | 2017-2018 | 115th Congress

Status

Sponsorship: Slight Partisan Bill (Democrat 3-1)
Status: Introduced on June 13 2017 - 25% progression, died in committee
Action: 2017-06-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Closing Loopholes for Orphan Drugs Act This bill amends the Public Health Service Act to revise the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Closing Loopholes for Orphan Drugs Act

Sponsors


History

DateChamberAction
2017-06-16HouseReferred to the Subcommittee on Health.
2017-06-13HouseReferred to the House Committee on Energy and Commerce.
2017-06-13HouseIntroduced in House

Subjects


US Congress State Sources


feedback